All In Biotech

NDA 022425 · Sanofi Aventis US

Multaq

Dronedarone Hydrochloride · Oral · Antiarrhythmic

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Oct 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 1, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

44

12 Phase 3, 4 recruiting

FAERS reports

10,242

7,225 serious, 673 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure, MULTAQ doubles the risk of death [see Clinical Studies (14.3) ] . MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure [see Contraindications (4) , Warnings and Precautions (5.1) ] . In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure [see Clinical Studies (14.4) ] . MULTAQ is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm [see Contraindications (4) , Warnings and Precautions (5.2) ]...

What it is approved for

From the label in effect Jan 27, 2026.

MULTAQ ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) ] . MULTAQ is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF ( 1 , 14 ).

Mechanism: The mechanism of action of dronedarone is unknown. Dronedarone has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each of these activities to the clinical effect is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MULTAQ · DRONEDARONE HYDROCHLORIDE EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dronedarone" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • atrial fibrillation1,428
  • dyspnoea850
  • fatigue627
  • off label use571
  • diarrhoea487
  • nausea479
  • drug interaction471
  • dizziness454
  • gastrointestinal haemorrhage421
  • asthenia385
  • drug ineffective337
  • blood creatinine increased311

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2009200
20101,088
20111,499
2012632
2013789
2014747
2015787
2016645
2017483
2018471
2019501
2020405
2021318
2022302
2023294
2024327
2025413
2026341

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Multaq (Dronedarone HCl)

2024 spending

$415M

Beneficiaries

72,761

318,776 claims

Per beneficiary

$5,700

$12.87 per unit

View as table
YearSpending
2020$342,150,558
2021$356,717,638
2022$386,678,239
2023$409,348,468
2024$414,751,255

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 67 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.